Skip to main content

Table 1 Baseline characteristics

From: T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides

  All patients n = 37 EGPAa n = 22 GPAa n = 15
Age (yrs) 55 ± 16 54 ± 16 55 ± 16
Gender (male) 13 (35%) 5 (23%) 8 (53%)
Cardiovascular risk factors
 Diabetes 7 (19%) 5 (23%) 2 (13%)
 Hypertension 13 (35%) 8 (36%) 5 (33%)
 Smokingb 13 (35%) 7 (32%) 6 (40%)
 Hyperlipidemia 6 (16%) 5 (23%) 1 (7%)
 Family history of CVD 11 (30%) 8 (36%) 3 (20%)
Obesity (BMI ≥ 30 kg/m2) 9 (24%) 5 (23%) 4 (27%)
Symptoms (multiple possible)
 Angina 6 (16%) 4 (18%) 2 (13%)
 Dyspnea 16 (43%) 12 (54%) 4 (27%)
 Palpitations 4 (11%) 4 (18%) -
 Syncope 1 (3%) 1 (5%) -
 ECG abnormality 11 (30%) 9 (41%) 2 (13%)
Years since diagnosis
  3 (0–11) 4 (0–11) 2 (0–11)
  < 1 12 (32%) 6 (27%) 6 (40%)
 1–4 11 (30%) 5 (23%) 6 (40%)
 5–9 11 (30%) 10 (46%) 1 (7%)
  ≥ 10 3 (8%) 1 (5%) 2 (13%)
Disease Activity
 BVAS 5.5 (1–14) 5 (3–8) 11.5 (0–24)
Hematocrit 0.39 (0.36–0.42) 0.4 (0.38–0.42) 0.38 (0.32–0.42)
Medication
 Beta-blockers 9 (24%) 6 (27%) 3 (20%)
 ARB 14 (38%) 7 (32%) 7 (47%)
 ASA 5 (14%) 5 (23%) -
 CCB 8 (22%) 4 (18%) 4 (27%)
 Statins 3 (8%) 2 (9%) 1 (7%)
 Diuretics 8 (22%) 7 (32%) 1 (7%)
 Steroids 37 (100%) 22 (100%) 15 (100%)
 NSAID 1 (3%) 1 (5%) -
 Antibodies 2 (5%) 1 (5%) 1 (7%)
 Cyclophosphamide 17 (46%) 4 (18%) 13 (87%)
 Azathioprine 4 (11%) 2 (9%) 2 (13%)
 Methotrexate 5 (14%) 4 (18%) 1 (7%)
  1. All values are n (%) or mean ± SD or interquartile ranges. apercentages based on number of EGPA/GPA patients, respectively, bcurrent or ever-smokers. EGPA eosinophilic granulomatosis with polyangiitis, GPA granulomatosis with polyangiitis, CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram, BVAS Birmingham vasculitis activity score, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug